Molecular mechanisms of host-derived CCL5 mediated mammary tumor growth
宿主来源的 CCL5 介导乳腺肿瘤生长的分子机制
基本信息
- 批准号:8138487
- 负责人:
- 金额:$ 17.28万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-09-07 至 2013-08-31
- 项目状态:已结题
- 来源:
- 关键词:Breast Cancer ModelBreast Cancer TreatmentCancer PatientCellsCessation of lifeDataFibroblastsFlow CytometryGoalsGrowthImmunofluorescence ImmunologicImmunologicsInfiltrationInflammationInflammatoryLungMalignant NeoplasmsMammary NeoplasmsMammary glandMediatingMolecularMusNeoplasm MetastasisNorth AmericaPlayProductionProgressive DiseaseRANTESRecruitment ActivityResearchResistanceRoleSignal TransductionSiteStaining methodStainsT cell responseT-LymphocyteTherapeutic AgentsTimeTumor AngiogenesisTumor-DerivedTumor-Secreted ProteinWild Type MouseWomanchemokineeosinophilmacrophagemalignant breast neoplasmneoplastic cellnew therapeutic targetpublic health relevancetumortumor growthtumor progression
项目摘要
DESCRIPTION (provided by applicant): Breast cancer is the most common type of malignant tumor among women in North America. Higher CCL5 production in breast cancer patients is associated with more progressive disease, indicating an important role of CCL5 in breast cancer progression. Recently, we have found that CCL5 deficient mice are highly resistant to mammary tumor growth and metastasis, with decreased numbers of macrophages infiltrated in the tumor. Therefore, we hypothesize that host CCL5 promotes mammary gland tumor progression by attracting macrophages migrated into the tumor. Blocking CCL5 signaling in a tumor-bearing host may serve as a new therapeutic target for breast cancer treatments. CCL5 is a chemokine produced by a variety of cells, including T cells, macrophages, fibroblasts and tumor cells. It plays an important role in inflammation by recruiting T cells, macrophages and eosinophils to inflammatory sites. CCL5 has been shown to be able to help in tumor angiogenesis, inhibit T cell responses and enhance growth of breast cancers. Using a syngeneic mammary tumor model, a recent study demonstrates that tumor-derived CCL5 is dispensable for tumor progression, suggesting it is the host-derived CCL5 which is important for breast cancer growth and metastasis. Our preliminary data demonstrates that mice genetically deficient in CCL5 (CCL5-KO) are resistant to tumor-induced death and develop few lung metastases. Consistent with these findings, neutralization of CCL5 in wild-type mice suppresses tumor growth and lung metastases. Further analyses of tumors by flow cytometry and immunofluorescence staining reveal a significant decrease of macrophages in the tumors of CCL5-KO mice. Our data provides direct evidence for the first time that host-derived CCL5 is essential for mammary tumor growth and metastasis. Since the mechanisms of host-derived CCL5 in promoting mammary tumor progression are largely unknown, we propose to investigate the mechanisms whereby host-derived CCL5 mediates macrophage infiltration into the tumors and the molecular mechanisms by which tumor cells induce CCL5 expression in host macrophages. Our long-term goal is to elucidate the cellular, molecular and immunologic mechanisms by which host CCL5 promotes breast cancer growth and metastasis, and to ultimately develop therapeutic agents that target CCL5 in a tumor-specific manner.
PUBLIC HEALTH RELEVANCE: Breast cancer is the most common type of malignant tumor among women in North America. Higher CCL5 production in breast cancer patients is associated with more progressive disease, indicating an important role of CCL5 in breast cancer progression. Our goal is to elucidate the cellular, molecular and immunologic mechanisms by which host CCL5 promotes breast cancer growth and metastasis, and to ultimately develop therapeutic agents that target CCL5 in a tumor-specific manner.
描述(由申请人提供):乳腺癌是北美女性中最常见的恶性肿瘤类型。乳腺癌患者中更高的CCL 5产生与更严重的疾病进展相关,表明CCL 5在乳腺癌进展中的重要作用。最近,我们发现CCL 5缺陷小鼠对乳腺肿瘤生长和转移具有高度抵抗性,肿瘤中浸润的巨噬细胞数量减少。因此,我们假设宿主CCL 5通过吸引巨噬细胞迁移到肿瘤中来促进乳腺肿瘤的进展。阻断荷瘤宿主中的CCL 5信号传导可能成为乳腺癌治疗的新靶点。CCL 5是由多种细胞产生的趋化因子,包括T细胞、巨噬细胞、成纤维细胞和肿瘤细胞。它通过将T细胞、巨噬细胞和嗜酸性粒细胞募集到炎症部位而在炎症中起重要作用。CCL 5已被证明能够帮助肿瘤血管生成,抑制T细胞反应并促进乳腺癌的生长。使用同基因乳腺肿瘤模型,最近的一项研究表明,肿瘤来源的CCL 5与肿瘤进展有关,这表明宿主来源的CCL 5对乳腺癌的生长和转移很重要。我们的初步数据表明,CCL 5基因缺陷的小鼠(CCL 5-KO)对肿瘤诱导的死亡具有抗性,并且很少发生肺转移。与这些发现一致,野生型小鼠中CCL 5的中和抑制肿瘤生长和肺转移。通过流式细胞术和免疫荧光染色对肿瘤的进一步分析揭示了CCL 5-KO小鼠肿瘤中巨噬细胞的显著减少。我们的数据首次提供了直接证据,表明宿主来源的CCL 5对乳腺肿瘤的生长和转移至关重要。由于宿主衍生的CCL 5在促进乳腺肿瘤进展中的机制在很大程度上是未知的,我们建议研究宿主衍生的CCL 5介导巨噬细胞浸润到肿瘤中的机制以及肿瘤细胞诱导宿主巨噬细胞中CCL 5表达的分子机制。我们的长期目标是阐明宿主CCL 5促进乳腺癌生长和转移的细胞,分子和免疫机制,并最终开发以肿瘤特异性方式靶向CCL 5的治疗药物。
公共卫生相关性:乳腺癌是北美妇女中最常见的恶性肿瘤。乳腺癌患者中更高的CCL 5产生与更严重的疾病进展相关,表明CCL 5在乳腺癌进展中的重要作用。我们的目标是阐明宿主CCL 5促进乳腺癌生长和转移的细胞,分子和免疫机制,并最终开发以肿瘤特异性方式靶向CCL 5的治疗药物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jianguo Liu其他文献
Jianguo Liu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jianguo Liu', 18)}}的其他基金
Role of RNA-binding protein in immune evasion of Mtb in macrophages
RNA结合蛋白在巨噬细胞中Mtb免疫逃避中的作用
- 批准号:
10634764 - 财政年份:2022
- 资助金额:
$ 17.28万 - 项目类别:
Role of RNA-binding protein in immune evasion of Mtb in macrophages
RNA结合蛋白在巨噬细胞中Mtb免疫逃避中的作用
- 批准号:
10511464 - 财政年份:2022
- 资助金额:
$ 17.28万 - 项目类别:
Pre-clinical testing the effects of MALT1 inhibitor on endocrine resistant breast cancer
MALT1抑制剂对内分泌耐药乳腺癌的临床前测试
- 批准号:
10579334 - 财政年份:2022
- 资助金额:
$ 17.28万 - 项目类别:
Pre-clinical testing the effects of MALT1 inhibitor on endocrine resistant breast cancer
MALT1抑制剂对内分泌耐药乳腺癌的临床前测试
- 批准号:
10435975 - 财政年份:2022
- 资助金额:
$ 17.28万 - 项目类别:
A new target for host-directed therapy against TB infection
针对结核感染的宿主定向治疗的新靶点
- 批准号:
10256733 - 财政年份:2020
- 资助金额:
$ 17.28万 - 项目类别:
A new target for host-directed therapy against TB infection
针对结核感染的宿主定向治疗的新靶点
- 批准号:
10057563 - 财政年份:2020
- 资助金额:
$ 17.28万 - 项目类别:
Mechanisms of IL28B genetic variation-mediated clearance of hepatitis C virus
IL28B基因变异介导的丙型肝炎病毒清除机制
- 批准号:
8445769 - 财政年份:2013
- 资助金额:
$ 17.28万 - 项目类别:
Mechanisms of IL28B genetic variation-mediated clearance of hepatitis C virus
IL28B基因变异介导的丙型肝炎病毒清除机制
- 批准号:
8732600 - 财政年份:2013
- 资助金额:
$ 17.28万 - 项目类别:
The role of tristetraprolin in control of breast cancer progression
三四脯氨酸在控制乳腺癌进展中的作用
- 批准号:
9079413 - 财政年份:2012
- 资助金额:
$ 17.28万 - 项目类别:
The role of tristetraprolin in control of breast cancer progression
三四脯氨酸在控制乳腺癌进展中的作用
- 批准号:
8221172 - 财政年份:2012
- 资助金额:
$ 17.28万 - 项目类别:
相似海外基金
Shoulder dysfunction and breast cancer treatment: biomechanical analysis of the impact of reconstruction and mastectomy
肩部功能障碍和乳腺癌治疗:重建和乳房切除术影响的生物力学分析
- 批准号:
488096 - 财政年份:2023
- 资助金额:
$ 17.28万 - 项目类别:
Operating Grants
Admin Suppl Gender-affirming estrogen therapy and breast cancer treatment outcome
行政补充性别肯定雌激素治疗和乳腺癌治疗结果
- 批准号:
10783533 - 财政年份:2023
- 资助金额:
$ 17.28万 - 项目类别:
Intensive Blood Pressure Control During Cardiotoxic Breast Cancer Treatment (PROTECT) Trial
心脏毒性乳腺癌治疗 (PROTECT) 试验期间强化血压控制
- 批准号:
10660289 - 财政年份:2023
- 资助金额:
$ 17.28万 - 项目类别:
Identification of small molecule inhibitors to exonuclease 1 for breast cancer treatment
鉴定用于乳腺癌治疗的核酸外切酶 1 小分子抑制剂
- 批准号:
10735307 - 财政年份:2023
- 资助金额:
$ 17.28万 - 项目类别:
Development of Breast Cancer Treatment Strategies Based on Dynamic Changes in Tumor Microenvironment Induced by Drug Modification
基于药物修饰引起的肿瘤微环境动态变化制定乳腺癌治疗策略
- 批准号:
23K08035 - 财政年份:2023
- 资助金额:
$ 17.28万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Using a Liquid Biopsy to Optimize Metastatic Breast Cancer Treatment
使用液体活检优化转移性乳腺癌治疗
- 批准号:
468409 - 财政年份:2022
- 资助金额:
$ 17.28万 - 项目类别:
Operating Grants
Improving Adherence to Breast Cancer Treatment Guidelines in Nigeria
提高尼日利亚对乳腺癌治疗指南的遵守率
- 批准号:
10684652 - 财政年份:2022
- 资助金额:
$ 17.28万 - 项目类别:
Multifunctional Nanotechnology Platform for Triple Negative Breast Cancer Treatment
用于三阴性乳腺癌治疗的多功能纳米技术平台
- 批准号:
10411148 - 财政年份:2022
- 资助金额:
$ 17.28万 - 项目类别:
Multifunctional Nanotechnology Platform for Triple Negative Breast Cancer Treatment
用于三阴性乳腺癌治疗的多功能纳米技术平台
- 批准号:
10672232 - 财政年份:2022
- 资助金额:
$ 17.28万 - 项目类别:
Improving Adherence to Breast Cancer Treatment Guidelines in Nigeria
提高尼日利亚对乳腺癌治疗指南的遵守率
- 批准号:
10351812 - 财政年份:2022
- 资助金额:
$ 17.28万 - 项目类别: